早期肝细胞癌术后近期复发风险和新辅助治疗研究进展

摘要

新辅助治疗作为早期肝细胞癌新兴的治疗策略，通过局部治疗和全身治疗，有助于降低术后高复发率，从而达到改善患者预后的目的。主要对早期肝癌术前所存在的高危复发因素和新辅助治疗的最新研究成果进行归纳和总结，为早期肝细胞癌新辅助治疗筛选适宜人群、制定合适治疗方案提供一定的临床思路。

关键词

早期肝细胞癌 / 复发 / 新辅助治疗 / 局部治疗 / 免疫治疗 / 靶向治疗

参考文献

[1] Parkin DM , Bray F , Ferlay J , et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108. DOI: 10.3322/canjclin.55.2.74.

[2] Bray F , Laversanne M , Sung H , et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.

[3] 中华人民共和国国家卫生健康委员会 . 原发性肝癌诊疗指南（2024年版）[J]. 肿瘤综合治疗电子杂志， 2024， 10(3): 17-68. DOI: 10.12151/JMCM.2024.03—02.

[4] Chan AWH , Zhong J , Berhane S , et al. Development of pre and postoperative models to predict early recurrence of hepatocellular carcinoma after surgical resection[J]. J Hepatol, 2018, 69(6): 1284-1293. DOI: 10.1016/j.jhep.2018.08.027.

[5] 孙惠川， 谢青， 荚卫东， 等 . 肝癌转化治疗中国专家共识（2021版）[J]. 中国实用外科杂志， 2021， 41(6)： 618-632. DOI: 10.3760/cma.j.cn115610—20210512—00223.

[6] 肖永胜, 郭磊, 周俭 . 原发性肝癌新辅助治疗进展[J]. 腹部外科， 2021， 34(1)： 1—3， 9. DOI: 10.3969/j.issn.1003—5591.2021.01.001.

[7] Zhou M , Wang H , Zeng X , et al. Mortality, morbidity, and risk factors in China and its provinces, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140—6736(19)30427—1.

[8] Bray F , Ferlay J , Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21609.

[9] 赵海涛， 毕新宇， 赵宏， 等 . 肝细胞癌新辅助及转化治疗中国专家共识[J]. 肝癌电子杂志， 2022， 9(1)： 23-28. DOI: 10.3969/j.issn.2095—7815.2022.01.002.

[10] 毕新宇, 黄振, 韩玥, 等 . 肝细胞癌新辅助及转化治疗中国专家共识（2023版）[J]. 肝癌电子杂志， 2023， 10(4)： 1-14. DOI: 10.1159/000541249.

[11] Hiroji S , Shogo T , Shigekazu T , et al. Tumor size drives the prognosis after hepatic resection of solitary hepatocellular carcinoma without vascular invasion[J]. J Gastrointest Surg, 2020, 24(5): 1040-1048. DOI: 10.1007/s11605—019—04273—2.

[12] Yao LQ , Chen ZL , Feng ZH , et al. Clinical features of recurrence after hepatic resection for early—stage hepatocellular carcinoma and long—term survival outcomes of patients with recurrence: a multi—institutional analysis[J]. Ann Surg Oncol, 2022, 29(8): 5206. DOI: 10.1245/s10434—022—11790—z.

[13] Zhu Y , Gu L , Chen T , et al. Factors influencing early recurrence of hepatocellular carcinoma after curative resection[J]. J Int Med Res, 2020, 48(8): 300060520945552. DOI: 10.1177/0300060520945552.

[14] Yan WT , Li C , Yao LQ , et al. Predictors and long—term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large—scale multicenter study[J]. Hepatobiliary Surg Nutr, 2023, 12(2): 155-168. DOI: 10.21037/hbsn—21—288.

[15] Wang MD , Sun LY , Qian GJ , et al. Prothrombin induced by vitamin K Absence—II versus alpha—fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: a retrospective cohort study[J]. Int J Surg, 2022, 105: 106843. DOI: 10.1016/j.ijsu.2022.106843.

[16] Liu Y , Wang ZX , Cao Y , et al. Preoperative inflammation—based markers predict early and late recurrence of hepatocellular carcinoma after curative hepatectomy[J]. HBPD Int, 2016, 15(3): 266-274. DOI: 10.1016/S1499—3872(16)60094—2.

[17] 吴美龙， 杨世忠， 董家鸿 . 中性粒—淋巴细胞比率与肝细胞癌肝部分切除术后总体生存的关系[J]. 中国现代普通外科进展， 2018， 21(11)： 855-859. DOI: 10.3969/j.issn.1009—9905.2018.11.004.

[18] 李巧媚， 周华邦， 叶斌， 等 . 血清HBV DNA水平及抗病毒治疗对HBV相关性肝细胞癌患者术后预后的影响[J]. 浙江医学， 2018， 40(1)： 3-7，15. DOI: 10.12056/j.issn.1006—2785.2018.40.1.2017—1717.

[19] Zhong FP , Zhang YJ , Liu Y , et al. Prognostic impact of surgical margin in patients with hepatocellular carcinoma: a meta analysis[J]. Medicine (Baltimore), 2017, 96(37): e8043. DOI: 10.1097/MD.0000000000008043.

[20] Shi M , Guo RP , Lin XJ , et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial[J]. Ann Surg, 2007, 245(1): 36-43. DOI: 10.1097/01.sla.0000231758.07868.71.

[21] Liao KX , Yang KJ , Cao L , et al. Laparoscopic anatomical versus non—anatomical hepatectomy in the treatment of hepatocellular carcinoma: a randomised controlled trial[J]. Int J Surg, 2022, 102: 106652. DOI: 10.1016/j.ijsu.2022.106652.

[22] Kobayashi A , Miyagawa S , Miwa S , et al. Prognostic impact of anatomical resection on early and late intrahepatic recurrence in patients with hepatocellular carcinoma[J]. J Hepatobiliary Pancreat Surg, 2008, 15(5): 515-521. DOI: 10.1007/s00534—007—1293—7.

[23] Si T , Chen Y , Ma D , et al. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta—analysis of random controlled trials[J]. Scand J Gastroenterol, 2016, 51(12): 1512-1519. DOI: 10.1080/00365521.2016.1216588.

[24] Shi HY , Wang SN , Wang SC , et al. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long—term outcome predictors[J]. J Surg Oncol, 2014, 109(5): 487-493. DOI: 10.1002/jso.23521.

[25] Li SH , Mei J , Cheng Y , et al. Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: a multi—center, phase 3, randomized, controlled clinical trial[J]. J Clin Oncol, 2023, 41(36): 5575-5585. DOI: 10.1200/JCO.23.00837.

[26] Tao C , Wu F , Wang H , et al. Clinical benefits of neoadjuvant radiotherapy on the postoperative recurrence of centrally located hepatocellular carcinoma: a real—world evidence based on phase Ⅱ clinical trial[J]. J Hepatocell Carcinoma, 2023, 10: 753-764. DOI: 10.2147/JHC.S403287.

[27] Wu F , Chen B , Dong D , et al. Neoadjuvant versus adjuvant radiotherapy for centrally located hepatocellular carcinoma: a propensity score matching study based on two prospective phase Ⅱ trials[J]. Ther Adv Med Oncol, 2025, 17: 17588359251342686. DOI: 10.1177/17588359251342686.

[28] Zhu XD , Yang XP , Yang C , et al. Neoadjuvant sorafenib for resectable hepatocellular carcinoma: a pilot study[J]. Cancer Commun (Lond), 2022, 40(12): 675-686. DOI: 10.1016/j.bcp.2022.115373.

[29] Wu JY , Fu YK , Wen TF , et al. Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high—risk of recurrence: A prospective, single—arm, phase 2 trial[J]. J Clin Oncol, 2024, 42(3): 503— 503. DOI: 10.1200/JCO.2024.42.3_suppl.503.

[30] Kaseb AO , Hasanov E , Cao H , et al. Pembrolizumab plus lenvatinib versus lenvatinib monotherapy as first—line therapy for advanced hepatocellular carcinoma: A randomized phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218. DOI: 10.1016/S2468—1253(21)00404—4.

[31] Antonio D'Alessio MD . Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME—HCC trial[J]. J Clin Oncol, 2021, 40(16): 4093— 4093. DOI: 10.1200/JCO.2022.40.16_suppl.4093.

[32] Li Z , Liu J , Zhang B , et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early—stage resectable hepatocellular carcinoma: the Notable—HCC phase 1b trial[J]. Nat Commun, 2024, 15(1): 3260. DOI: 10.1038/s41467—024—47420—3.

[33] Sun HC , Zhu XD , Wang K , et al. Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: a single—arm, multi—center, phase Ⅱ trial (NEOLEAP—HCC)[J]. J Clin Oncol, 2024, 42(suppl 16): 4120. DOI: 10.1200/JCO.2024.42.16_suppl.4120.

基金资助

国家自然科学基金重大项目(82090052)

清华大学精准医学科研项目(2022ZLA007)